Methods for treating eye disorders
First Claim
Patent Images
1. A method for treating an eye disorder, comprising:
- administering to an eye of a mammal an ophthalmic composition, wherein the ophthalmic composition is a solution and contains an ophthalmically acceptable carrier, a Clostridial toxin in an amount effective to treat the eye disorder when the composition is administered to an eye, a polyanionic component in amount effective to provide lubrication to the eye and a vasoconstrictor comprises from about 0.001% (w/v) to about 0.5% (w/v) of the composition, thereby treating the eye disorder.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and/or a Clostridial botulinum.
65 Citations
11 Claims
-
1. A method for treating an eye disorder, comprising:
administering to an eye of a mammal an ophthalmic composition, wherein the ophthalmic composition is a solution and contains an ophthalmically acceptable carrier, a Clostridial toxin in an amount effective to treat the eye disorder when the composition is administered to an eye, a polyanionic component in amount effective to provide lubrication to the eye and a vasoconstrictor comprises from about 0.001% (w/v) to about 0.5% (w/v) of the composition, thereby treating the eye disorder. - View Dependent Claims (2, 3, 4, 5)
-
6. A method for treating an eye disorder, comprising:
administering to an eye of a mammal an ophthalmic composition, wherein the ophthalmic composition is a solution and contains an ophthalmically acceptable carrier, a Clostridial toxin in an amount effective to treat the eye disorder when the composition is administered to an eye, a polyanionic component comprising from about 0.05% (w/v) to about 5% (w/v) of the composition, and a vasoconstrictor, thereby treating the eye disorder. - View Dependent Claims (7, 8, 9, 10, 11)
Specification